Epizyme, Inc. (NASDAQ:EPZM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday.

According to Zacks, “Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. Additionally, its attempts to evaluate tazemetostat in combination with anti-PD 1 or PDL-1 agent are also encouraging. We believe, the  company’s collaboration agreement with Celgene for small-molecule HMT inhibitors including pinometostat is a big positive. Epizyme’s share price has also outperformed the Zacks classified Medical/Biomedical Genetics industry year to date. However, with no approved product in its portfolio, Epizyme is highly dependent on its collaboration partners for top-line growth.”

Other analysts also recently issued reports about the stock. Cann reissued an “outperform” rating and set a $26.00 target price on shares of Epizyme in a research note on Wednesday, April 12th. HC Wainwright reissued a “buy” rating on shares of Epizyme in a research note on Friday, May 19th. Royal Bank Of Canada reissued an “outperform” rating and set a $20.00 target price (up from $19.00) on shares of Epizyme in a research note on Wednesday, May 10th. Cowen and Company reissued a “buy” rating on shares of Epizyme in a research note on Wednesday, June 7th. Finally, Wedbush reissued an “outperform” rating and set a $24.00 target price on shares of Epizyme in a research note on Thursday, May 18th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $23.75.

Epizyme (NASDAQ:EPZM) traded down 3.69% during trading on Monday, reaching $14.35. The company’s stock had a trading volume of 203,582 shares. Epizyme has a 52 week low of $7.02 and a 52 week high of $18.50. The firm’s market capitalization is $837.44 million. The firm has a 50-day moving average price of $14.52 and a 200-day moving average price of $13.96.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.07. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 55.41%. On average, equities analysts anticipate that Epizyme will post ($2.42) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Lowers Epizyme, Inc. (NASDAQ:EPZM) to Hold” was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/17/zacks-investment-research-lowers-epizyme-inc-nasdaqepzm-to-hold.html.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $16.11, for a total value of $241,650.00. Following the completion of the sale, the insider now directly owns 22,228 shares in the company, valued at $358,093.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew E. Singer sold 3,024 shares of the company’s stock in a transaction on Friday, June 30th. The stock was sold at an average price of $15.50, for a total transaction of $46,872.00. Following the completion of the sale, the chief financial officer now owns 40,529 shares of the company’s stock, valued at $628,199.50. The disclosure for this sale can be found here. Insiders sold 40,524 shares of company stock worth $632,397 over the last ninety days. 25.20% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the company. Foresite Capital Management II LLC boosted its stake in shares of Epizyme by 1.1% in the first quarter. Foresite Capital Management II LLC now owns 1,543,118 shares of the biopharmaceutical company’s stock worth $26,464,000 after buying an additional 16,481 shares in the last quarter. Foresite Capital Management III LLC boosted its stake in shares of Epizyme by 12.7% in the first quarter. Foresite Capital Management III LLC now owns 681,922 shares of the biopharmaceutical company’s stock worth $11,695,000 after buying an additional 76,683 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Epizyme by 3.1% in the first quarter. Teachers Advisors LLC now owns 69,922 shares of the biopharmaceutical company’s stock worth $1,199,000 after buying an additional 2,093 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Epizyme by 0.5% in the first quarter. Principal Financial Group Inc. now owns 94,173 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 515 shares in the last quarter. Hedge funds and other institutional investors own 81.63% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Get a free copy of the Zacks research report on Epizyme (EPZM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.